Compare Cytokinetics Inc (CYTK) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Texas Instruments Incorporated — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Texas Instruments Incorporated trades at $291.62 (market cap $263.91B). The key difference: Texas Instruments Incorporated is far larger — about 31× Cytokinetics Inc's market cap, and Texas Instruments Incorporated pays a 2.1% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Texas Instruments Incorporated for 76 Days on average.
| CYTK | TXN | |
|---|---|---|
Market Cap | $8.50B | $263.91B |
Volume | 2,395,556 | 4,544,426 |
Sector | Health | Technology |
52-Week High | $87.26 | $332.35 |
52-Week Low | $54.76 | $153.33 |
Typical Hold Time | 19 Days | 76 Days |
Enterprise Value | $8.60B | $270.96B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Texas Instruments (TXN) trades at $288.2, down 3.06% today amid a semiconductor sector sell-off. The stock shows strong technical momentum with bullish moving averages and key support at $286. Fundamentally, Q2 2026 EPS beat expectations at $2.14 versus $1.91, driven by data center sales doubling. Revenue growth is accelerating with 2026 projections at $19.5B, while maintaining robust profitability with 31.11% net margins. Recent dividend payments and institutional buying by CalSTRS signal confidence.
Outlook remains positive with 47.7% analyst buy ratings and $325 consensus price target offering 13% upside. Key catalysts include AI-driven data center expansion and industrial recovery. Risks include premium valuation (P/E 43.9) and cyclical semiconductor demand. The earnings recovery trajectory supports continued growth despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
